Literature DB >> 24145038

Binding of a sialic acid-recognizing lectin Siglec-9 modulates adhesion dynamics of cancer cells via calpain-mediated protein degradation.

Ilhamjan Sabit1, Noboru Hashimoto, Yasuyuki Matsumoto, Toshiyuki Yamaji, Keiko Furukawa, Koichi Furukawa.   

Abstract

Although regulatory mechanisms for immune cells with inhibitory signals via immunoreceptor tyrosine-based inhibitory motifs are well known, signals transduced via interaction between Siglecs and sialyl compounds on their counterreceptors into target cells have not been reported to date. In this study, we found that an astrocytoma cell line, AS, showed detachment from culture plates when co-cultured with Siglec-9-expressing cells and/or soluble Siglec-9. Moreover, detached AS cells regrew as co-cultured cells with Siglec-9-deficient cells. They also showed increased motility and invasiveness upon Siglec-9 binding. In immunoblotting, rapid degradation of focal adhesion kinase (FAK) and related signaling molecules such as Akt, paxillin, and p130Cas was observed immediately after the co-culture. Despite degradation of these molecules, increased p-Akt was found at the front region of the cytoplasm, probably reflecting increased cell motility. Calpain was considered to be a responsible protease for the protein degradation by the inhibition experiments. These results suggest that protein degradation of FAK and related molecules was induced by Siglec-9 binding to its counterreceptors via sialylglycoconjugates, leading to the modulation of adhesion kinetics of cancer cells. Thus, this might be a mechanism by which cancer cells utilize Siglec-9-derived signals to escape from immunosurveillance.

Entities:  

Keywords:  Adhesion; Calpain; Focal Adhesion Kinase; Lectin; Protein Degradation; Sialic Acid

Mesh:

Substances:

Year:  2013        PMID: 24145038      PMCID: PMC3853289          DOI: 10.1074/jbc.M113.513192

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions.

Authors:  Michael D Schaller
Journal:  J Cell Sci       Date:  2010-04-01       Impact factor: 5.285

2.  Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9.

Authors:  Mariko Ohta; Akiko Ishida; Munetoyo Toda; Kaoru Akita; Mizue Inoue; Keishi Yamashita; Masashi Watanabe; Takeomi Murata; Taichi Usui; Hiroshi Nakada
Journal:  Biochem Biophys Res Commun       Date:  2010-10-29       Impact factor: 3.575

Review 3.  Focal adhesion kinase: exploring Fak structure to gain insight into function.

Authors:  Jessica E Hall; Wei Fu; Michael D Schaller
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

4.  Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes.

Authors:  J Q Zhang; G Nicoll; C Jones; P R Crocker
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.

Authors:  T Angata; A Varki
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

Review 6.  Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis.

Authors:  Xiaofeng Zhao; Jun-Lin Guan
Journal:  Adv Drug Deliv Rev       Date:  2010-11-29       Impact factor: 15.470

Review 7.  Focal adhesion kinase as a cancer therapy target.

Authors:  Vita M Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

8.  Regulation of adhesion dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK).

Authors:  Keefe T Chan; David A Bennin; Anna Huttenlocher
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

Review 9.  Siglecs and immune regulation.

Authors:  Shiv Pillai; Ilka Arun Netravali; Annaiah Cariappa; Hamid Mattoo
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

10.  A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis.

Authors:  B Li; S A Desai; R A MacCorkle-Chosnek; L Fan; D M Spencer
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

View more
  5 in total

Review 1.  Viewing Siglecs through the lens of tumor immunology.

Authors:  Isabella Fraschilla; Shiv Pillai
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

2.  Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Authors:  Heinz Läubli; Frederico Alisson-Silva; Michal A Stanczak; Shoib S Siddiqui; Liwen Deng; Andrea Verhagen; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

Review 3.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

4.  Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Authors:  Heinz Läubli; Oliver M T Pearce; Flavio Schwarz; Shoib S Siddiqui; Lingquan Deng; Michal A Stanczak; Liwen Deng; Andrea Verhagen; Patrick Secrest; Chrissy Lusk; Ann G Schwartz; Nissi M Varki; Jack D Bui; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-15       Impact factor: 11.205

5.  Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.

Authors:  Yuliang Wu; Wei Huang; Yutong Xie; Chunyan Wang; Ning Luo; Yingying Chen; Liefu Wang; Zhongping Cheng; Zhengliang Gao; Shupeng Liu
Journal:  Front Mol Biosci       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.